The FDA and European Medicines Agency (EMA) have awarded orphan drug designation to CPI-008 (cRGD-ZW800-1), a novel ...
The sheer growth of small biotechs and mid‑sized pharma companies entering the field has reshaped expectations of Contract Development and Manufacturing Organisations (CDMOs).
Nimbus and Eli Lilly collaborate to develop an oral treatment for obesity, leveraging computational chemistry and structure-based drug design. Nimbus Therapeutics and Eli Lilly announce their ...
The Trump administration's deep cuts in U.S. foreign health aid had a devastating impact. Yet there were achievements of note ...
The "Celiac Disease Market - A Global and Regional Analysis: Focus on Country and Region - Analysis and Forecast, 2025-2035" has been added to ResearchAndMarkets.com's offering.The global celiac ...
Insilico Medicine (3696.HK), a clinical-stage drug discovery and development company driven by generative artificial ...
The FDA has qualified its first artificial intelligence tool to help drug developers evaluate fatty liver disease in their clinical trials. The agency gave a green light to the AI-Based Histologic ...
One of the most complex issues in health care is the development and commercialization of treatments and cures for rare and orphan diseases — those for which no drug has been developed because its ...
The rapid advancement of artificial intelligence (AI) is transforming the field of structural biology. In May 2024, DeepMind and Isomorphic Labs launched AlphaFold 3 (AF3), a revolutionary AI system ...
The challenge is real, but so is the opportunity: together, we can make prevention a priority and create healthier, more resilient communities. Substance abuse continues to be one of the most pressing ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback